所属している研究会から新しい情報が届いた。
ビタミンC点滴と抗がん剤の併用で生存期間の延長が期待できる。
*********************
文献情報】
高濃度ビタミンC点滴療法と化学療法の併用で膵臓癌の生存期間が２倍に延長
──────────────────────────────────
2月5日にアイオワ大学からステージ４の膵臓がんにgemicitabinと高濃度
ビタミンC点滴療法を併用する第１相試験の結果がCancer Chemother Pharmacol.
に発表されました。
内容は次の通りです。
「ステージ４の膵臓がん９例に週２回の15-125gのIVCで平均生存期間は13ヶ月
と従来の5.65ヶ月を大幅に延長。１例は腫瘍サイズが９分の１に縮小、１例は15
ヶ月、１例は29ヶ月生存。IVCをすることで問題となるような副作用は認められな
かった。この結果は今後の臨床研究を積極的に進める価値があることを示した。」
http://www.ncbi.nlm.nih.gov/pubmed/23381814
The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.
Cancer Chemother Pharmacol. 2013 Feb 5. [Epub ahead of print]
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.
Welsh JL, Wagner BA, Van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ.
Source
Department of Surgery, 1528 JCP-UIHC, The University of Iowa Carver College of Medicine, Iowa City, IA, 52242, USA.
Abstract
BACKGROUND:
Treatment for pancreatic cancer with pharmacological ascorbate (ascorbic acid, vitamin C) decreases tumor progression in preclinical models. A phase I clinical trial was performed to establish safety and tolerability of pharmacological ascorbate combined with gemcitabine in patients with biopsy-proven stage IV pancreatic adenocarcinoma.
DESIGN:
Nine subjects received twice-weekly intravenous ascorbate (15-125 g) employing Simon's accelerated titration design to achieve a targeted post-infusion plasma level of ≥350 mg/dL (≥20 mM). Subjects received concurrent gemcitabine. Disease burden, weight, performance status, hematologic and metabolic laboratories, time to progression and overall survival were monitored.
RESULTS:
Mean plasma ascorbate trough levels were significantly higher than baseline (1.46 ± 0.02 vs. 0.78 ± 0.09 mg/dL, i.e., 83 vs. 44 μM, p < 0.001). Adverse events attributable to the drug combination were rare and included diarrhea (n = 4) and dry mouth (n = 6). Dose-limiting criteria were not met for this study. Mean survival of subjects completing at least two cycles (8 weeks) of therapy was 13 ± 2 months.
CONCLUSIONS:
Data suggest pharmacologic ascorbate administered concurrently with gemcitabine is well tolerated. Initial data from this small sampling suggest some efficacy. Further studies powered to determine efficacy should be conducted.
PMID:
23381814
[PubMed - as supplied by publisher]